v3.8.0.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenue:      
Tc99m tilmanocept sales revenue $ 39,601 $ 19,075
Tc99m tilmanocept license revenue 100,000 1,795,625 1,133,333
Tc99m tilmanocept royalty revenue 9,126
Grant and other revenue 1,701,311 3,136,408 1,860,953
Total revenue 1,810,437 4,971,634 3,013,361
Cost of goods sold 3,651 62,260 3,226
Gross profit 1,806,786 4,909,374 3,010,135
Operating expenses:      
Research and development 4,513,842 7,138,080 10,562,729
Selling, general and administrative 11,169,951 7,920,036 10,888,146
Total operating expenses 15,683,793 15,058,116 21,450,875
Loss from operations [1] (13,877,007) (10,148,742) (18,440,740)
Other income (expense):      
Interest income (expense), net 168,971 (4,866) (1,269,916)
Equity in loss of R-NAV, LLC (15,159) (305,253)
Loss on disposal of investment in R-NAV, LLC (39,732)
Change in fair value of financial instruments 153,357 2,858,524 (614,782)
Loss on extinguishment of debt (4,201,668) (2,440,714)
Other, net (33,339) (27,919) 26,808
Total other income (expense), net (3,912,679) [2] 2,770,848 (4,603,857)
Loss before income taxes (17,789,686) (7,377,894) (23,044,597)
Benefit from income taxes 4,062,489
Loss from continuing operations (13,727,197) (7,377,894) (23,044,597)
Discontinued operations, net of tax effect:      
Loss from discontinued operations (490,758) (6,931,137) (4,518,938) [3]
Gain on sale 89,163,811
Net income (loss) 74,945,856 (14,309,031) (27,563,535)
Less loss attributable to noncontrolling interest (210) (648) (855)
Deemed dividend on beneficial conversion feature of MT Preferred Stock (46,000)
Net income (loss) attributable to common stockholders $ 74,946,066 $ (14,308,383) $ (27,608,680)
Income (loss) per common share (basic):      
Continuing operations (in dollars per share) $ (0.08) $ (0.05) $ (0.15)
Discontinued operations (in dollars per share) 0.55 (0.04) (0.03)
Attributable to common stockholders (in dollars per share) $ 0.47 $ (0.09) $ (0.18)
Weighted average shares outstanding (basic) (in shares) 161,592,569 155,422,384 151,180,222
Income (loss) per common share (diluted):      
Continuing operations (in dollars per share) $ (0.08) $ (0.05) $ (0.15)
Discontinued operations (in dollars per share) 0.53 (0.04) (0.03)
Attributable to common stockholders (in dollars per share) $ 0.45 $ (0.09) $ (0.18)
Weighted average shares outstanding (diluted) (in shares) 166,016,458 155,422,384 151,180,222
[1] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[2] Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.
[3] Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).

Source